chevron_left
Tariffs Policy Impacts on Pharma and Medtech
In an era of shifting global trade dynamics, the volatile U.S. tariff landscape could have broad implications for pharma and medtech. Since February 2025, evolving White House tariff strategies have created uncertainty that’s rippled across earnings reports, forecasts and the stock market. The messaging has continued to rapidly shift – on both the tariff level and the implementation date.
Our experts dive into the data in our eBook to answer such questions as:
- What the potential impacts of the U.S. administration’s tariffs are for life science companies vis-a-vis:
- Supply chain resiliency
- Pricing
- Market access
- Is onshoring of API/FDF/FPP and generics manufacturing doable in the near term and what sorts of costs would be incurred?
- Could free trade zones ease the pain of tariffs?
- How are these policies affecting patients, clinicians, hospitals and payers?
